PD-L1 Antikörper (Extracellular Domain) (Biotin)

Produktnummer ABIN6992233

Dieses Maus Monoklonal-Antikörper erkennt spezifisch PD-L1 in ELISA. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für PD-L1 Antikörper (Extracellular Domain) (Biotin) (ABIN6992233)

Target: PD-L1 (CD274 (PD-L1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PD-L1 Antikörper ist konjugiert mit Biotin

Applikation: ELISA

Klon: 8E12

Produktdetails anti-PD-L1 Antikörper (Biotin)

Bindungsspezifität: Extracellular Domain

Aufreinigung: PD-L1 Antibody is supplied as protein A purified IgG1.

Immunogen: PD-L1 antibody was raised against the extracellular domain of human PD-L1.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: PD-L1 antibody can be used for as detection antibody in Sandwich Elisa at 1 μ,g/mL.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PD-L1 Antibody is supplied in PBS containing 1 % BSA and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,4 °C

Informationen zur Lagerung: PD-L1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: PDL1

Hintergrund: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

Gen-ID: 29126

NCBI Accession: NP_054862

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints